AIM ImmunoTech (LSE:0A4Y) - Stock Price, News & Analysis

0A4Y Stock Overview

An immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.

About the company

0A4Y fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 66.05% per year

Risk Analysis

Makes less than USD$1m in revenue ($201K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($16M)

Shareholders have been diluted in the past year

AIM ImmunoTech Inc. Competitors

ProBiotix Health

OFEX:PBX

UK£10.7m

Synairgen

AIM:SNG

UK£9.2m

Hemogenyx Pharmaceuticals

LSE:HEMO

UK£17.4m

Verici Dx

AIM:VRCI

UK£8.2m

Price History & Performance

Summary of all time highs, changes and price drops for AIM ImmunoTech
Historical stock prices
Current Share Price	US$0.26
52 Week High	US$0.60
52 Week Low	US$0.24
Beta	-0.39
11 Month Change	-7.55%
3 Month Change	-7.98%
1 Year Change	-51.53%
33 Year Change	-85.39%
5 Year Change	n/a
Change since IPO	-98.97%

Recent updates

Shareholder Returns

	0A4Y	GB Biotechs	GB Market
7D	-5.2%	-3.5%	-0.3%
1Y	-51.5%	-16.7%	8.7%

Return vs Industry: 0A4Y underperformed the UK Biotechs industry which returned -16.1% over the past year.

Return vs Market: 0A4Y underperformed the UK Market which returned 8.8% over the past year.

Price Volatility

Is 0A4Y's price volatile compared to industry and market?
0A4Y volatility
0A4Y Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.8%
Market Average Movement	4.6%
10% most volatile stocks in GB Market	9.6%
10% least volatile stocks in GB Market	2.5%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine 0A4Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1966	27	Thomas Equels	aimimmuno.com

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

AIM ImmunoTech Inc. Fundamentals Summary

How do AIM ImmunoTech's earnings and revenue compare to its market cap?
0A4Y fundamental statistics
Market cap	US$15.83m
Earnings (TTM)	-US$28.04m
Revenue (TTM)	US$201.00k

78.7x

P/S Ratio

-0.6x

P/E Ratio

Is 0A4Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4Y income statement (TTM)
Revenue	US$201.00k
Cost of Revenue	US$58.00k
Gross Profit	US$143.00k
Other Expenses	US$28.19m
Earnings	-US$28.04m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 15, 2024

Earnings per share (EPS)	-0.44
Gross Margin	71.14%
Net Profit Margin	-13,952.74%
Debt/Equity Ratio	43.2%

How did 0A4Y perform over the long term?

See historical performance and comparison

0A4Y Stock Overview

Rewards

Risk Analysis

AIM ImmunoTech Inc. Competitors

OFEX:PBX

UK£10.7m

AIM:SNG

UK£9.2m

LSE:HEMO

UK£17.4m

AIM:VRCI

UK£8.2m

Price History & Performance

Recent News & Updates

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Ted D. Kellner Sends a Notice to AIM ImmunoTech

Recent updates

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Ted D. Kellner Sends a Notice to AIM ImmunoTech

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Second quarter 2024 earnings released: US$0.035 loss per share (vs US$0.10 loss in 2Q 2023)

Todd Deutsch Sends Notice of Intent to Nominate Candidates to AIM ImmunoTech Board

AIM ImmunoTech Inc. Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of A Combination Therapy

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

New major risk - Financial position

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.076 loss in 1Q 2023)

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$0.60 loss per share (vs US$0.41 loss in FY 2022)

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.13 loss in 3Q 2022)

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen

AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation

Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.10 loss in 2Q 2022)

AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022)

Insufficient new directors

Insufficient new directors

AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod)

Executive Vice Chairman recently bought US$50k worth of stock

Insufficient new directors

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Insufficient new directors

AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen

ASFV Committee Issues a Statement on Ruling in Delaware Action

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech

AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions

Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma

AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer

Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data

Insufficient new directors

AIM ImmunoTech Inc. Provides Update on Ampligen Long COVID Development Program